Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a verbal warning into a lawsuit. In a lawsuit filed Thursday in a New ...

Merck expects $200 million in added tariff costs, primarily impacting gross margins. The company has invested $12 billion since 2017, with another $9 billion planned to expand U.S. manufacturing ...

Caroline Litchfield; Chief Financial Officer, Executive Vice President; Merck & Co Inc Dean Li; Executive Vice President, President - Merck Research Laboratories; Merck & Co Inc Thank you for ...

Merck KGaA is edging closer to the SpringWorks deal, which was first rumoured in February, confirming late-stage negotiations at an estimated price of $47 per share – potentially valuing the ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid an escalating trade war between the US and China, where demand for its blockbuster Gardasil vaccine is ...

Halozyme Therapeutics (NASDAQ:HALO) on Thursday announced a lawsuit against Merck (NYSE:MRK) over allegations that an injectable version of the New Jersey-based pharma giant’s blockbuster cancer ...

A biotech company is suing Merck & Co. over its easier-to-use version of its blockbuster cancer treatment Keytruda, alleging the pharmaceutical giant violated its intellectual property.

Merck said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the U.S. and China. The estimate doesn’t account for the possibility that ...

Merck & Co. cut its 2025 earnings outlook, partly to account for recently imposed tariffs that it projects will total $200 million. The projection comes in light of the tariffs implemented so ...

Halozyme Therapeutics is suing Merck for patent infringement. The San Diego biotechnology company said Thursday it believes a proposed form of Merck's cancer medicine Keytruda uses a formulation ...

Merck, while steadfast in its manufacturing push that aligns with the administration’s focus, is no different as it prepares for challenges ahead. While the company reaffirmed its full-year ...

Announcing better-than-expected financials for Q1 2025 on Thursday, Merck (NYSE:MRK) lowered its full-year outlook for earnings to account for various headwinds, including a $200M impact related ...